Clinical Trial Update: A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa

View source ↗

Summary

A completed clinical trial investigating risk factors for anti-erythropoietin antibodies leading to pure red-cell aplasia in patients with chronic kidney diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Pure Red Cell Aplasia

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Pure Red-cell Aplasia | Status: COMPLETED